Full year results 2010 - continued strong revenue growth
24-02-11 kl. 24/2 2011 14:03 | Exiqon 17,80 (0,00%)
Copenhagen, Denmark, 2011-02-24 15:03 CET (GLOBE NEWSWIRE) --Reported figures are for the full reporting period unless otherwise stated.
Figures for the comparable reporting period last year is stated in parenthesis
after realized figures. Comparative numbers in the statement of comprehensive
income does not include numbers from discontinued operations. Comparative
numbers for 2008 in the statement of financial position include numbers from
the discontinued operations.
Exiqon A/S (NASDAQ OMX Copenhagen: “EXQ”) today announced results for 2010. For
the full year of 2010, revenue increased to DKK 93.5 million or 38% when
excluding (14% when including) one-time payments in the comparative numbers for
the same period in 2009. Operating expenses was DKK 88.3 million (DKK 188.1
million). Net loss from continued operations was DKK 42.1 million (DKK 146.7
million).
In the fourth quarter of 2010, organic growth in life science research product
sales was 51% when excluding OEM sales and reagent sales associated with
license agreements. Operating expenses decreased 75% to DKK 23.8 million in the
fourth quarter. In the fourth quarter of 2010, the net loss from continued
operations was DKK 8.6 million (DKK 89.9 million).
Highlights
-- For the full year of 2010, revenue increased 14% to DKK 93.5 million (DKK
82.2 million). The organic growth in life science research product sales
(including Services) was 52% in 2010 when excluding OEM sales and reagent
sales associated with license agreements.
-- In the fourth quarter of 2010, revenue increased 42% to DKK 27.8 million
(DKK 19.6 million) due to a strong organic growth in product sales. Organic
growth in life science research product sales (including Services) was 51%
in the fourth quarter of 2010, when excluding OEM sales and reagent sales
associated with license agreements.
-- For the full year of 2010, operating expenses decreased 53% to DKK 88.3
million (DKK 188.1 million) as a result of the restructuring of Exiqon Life
Sciences that was undertaken in 2009.
-- In the fourth quarter of 2010, operating expenses decreased 75% to DKK 23.8
million (DKK 95.4 million).
-- For the full year of 2010, gross profit improved 19% to DKK 48.1 million
(DKK 40.5 million).
-- In the fourth quarter of 2010, gross profit improved 74% to DKK 15.4
million (DKK 8.9 million).
-- For the full year of 2010, EBIT improved 73% to DKK -40.2 million (DKK
-147.7 million).
-- In the fourth quarter of 2010, EBIT improved 91% to DKK -8.4 million (DKK
-89.5 million).
-- For the full year of 2010, net loss from continued operations was DKK 42.1
million (DKK 146.7 million). Basic EPS from continued operations amounted
to DKK -1.32 (DKK -4.84).
-- In the fourth quarter of 2010, net loss from continued operations was DKK
8.6 million (DKK 89.9 million). Basic EPS from continued operations
amounted to DKK -0.25 (DKK -2.97).
Lars Kongsbak, President and CEO, says: ”I am very pleased with the strong
improvement of all key financial figures. We have managed to effectively
restructure the business which has resulted in a reduced cost base, and at the
same time significantly grow the top-line. The fourth quarter was the best ever
in Exiqon's history. We have a strong basis for reaching our 2011 goal of total
revenue of DKK 105-115 million and an EBITDA of approximately DKK 0.00 with a
variation of +/- DKK 5 million.”
Additional information:
Lars Kongsbak, CEO, tel. +45 4566 0888 (cell: +45 4090 2101)
Hans Henrik Chrois Christensen, CFO, tel. +45 4566 0888 (cell: +45 4090 2131)
See the full release and the annual report in the attached PDF files or at
www.exiqon.com/investor.
Skriv en kommentarer til denne artikel:
Send kommentar

Se flere nyheder om Exiqon



